Clinical Efficacy of Combined Fixed Ophthalmic Hypotensive Drugs in Primary Open-Angle Glaucoma

Abstract

Patients with PAAG without IOP compensation received a fixed combination of 0.004% travoprost and 0.5% timolol maleate (Duotrav) or 1% brinzolamide and 0.5% timolol maleate (Azarga). Patients were prescribed fixed combinations in the form of a change in the drug therapy regimen when PAAG was directly diagnosed and if it was ineffective. If IOP does not reach target level after 1 month. treatment, penetrating or non-penetrating glaucoma surgery was performed. The follow-up period lasted 6 months.

Patients with PAAG and uncompensated IOP received a fixed combination of travoprost 0.004% and timolol maleate 0.5% (Duotrav) or brinzolamide 1% and timolol maleate 0.5% (Azarga). Patients were assigned the combination either after diagnosis of POAG or as transition from prior treatment. Antiglaucoma surgery was performed in these patients if the IOP level did not reach the prescribed level within 1 month. The follow-up period lasted 6 months. 218 patients (220 eyes) were included in the study. Treatment with a fixed combination of topical antihypertensive drugs made it possible to achieve the target intraocular pressure in 88% of patients.